Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 HSV-targeted immunotherapy in HSV-2 seronegative Japanese adults
jRCT2031230226Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2023
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in genital herpes and Genital Herpes Type 2 (HSV-2) (3 arms), sponsored by GSK. Primary endpoints: Percentage of participants with solicited administration site events, Percentage of participants with solicited systemic events and 6 more. Started Aug 2023; status: completed.
02
Conditions
genital herpesGenital Herpes Type 2 (HSV-2)
Beyond the preview
Go deeper on jRCT2031230226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230226.